Eli Lilly And Stock Return On Equity
| LLY Stock | USD 745.95 4.82 0.64% |
Eli Lilly and fundamentals help investors to digest information that contributes to Eli Lilly's financial success or failures. It also enables traders to predict the movement of Eli Stock. The fundamental analysis module provides a way to measure Eli Lilly's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eli Lilly stock.
| Last Reported | Projected for Next Year | ||
| Return On Equity | 0.49 | 0.26 |
Eli | Return On Equity |
Eli Lilly and Company Return On Equity Analysis
Eli Lilly's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Eli Lilly Return On Equity | 0.48 |
Most of Eli Lilly's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eli Lilly and is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Eli Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Eli Lilly is extremely important. It helps to project a fair market value of Eli Stock properly, considering its historical fundamentals such as Return On Equity. Since Eli Lilly's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eli Lilly's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eli Lilly's interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Eli Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Eli Lilly and has a Return On Equity of 0.4844. This is 102.02% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all United States stocks is notably lower than that of the firm.
Did you try this?
Run Idea Optimizer Now
Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
| All Next | Launch Module |
Eli Lilly ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eli Lilly's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eli Lilly's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Eli Fundamentals
| Return On Equity | 0.48 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.34 % | ||||
| Current Valuation | 699.33 B | ||||
| Shares Outstanding | 950.77 M | ||||
| Shares Owned By Insiders | 0.16 % | ||||
| Shares Owned By Institutions | 84.31 % | ||||
| Number Of Shares Shorted | 5.42 M | ||||
| Price To Earning | 54.92 X | ||||
| Price To Book | 66.34 X | ||||
| Price To Sales | 20.94 X | ||||
| Revenue | 34.12 B | ||||
| Gross Profit | 21.91 B | ||||
| EBITDA | 12.46 B | ||||
| Net Income | 5.24 B | ||||
| Cash And Equivalents | 2.07 B | ||||
| Cash Per Share | 2.97 X | ||||
| Total Debt | 25.23 B | ||||
| Debt To Equity | 1.58 % | ||||
| Current Ratio | 1.13 X | ||||
| Book Value Per Share | 11.98 X | ||||
| Cash Flow From Operations | 4.24 B | ||||
| Short Ratio | 1.82 X | ||||
| Earnings Per Share | 5.82 X | ||||
| Price To Earnings To Growth | 1.43 X | ||||
| Target Price | 826.53 | ||||
| Number Of Employees | 43 K | ||||
| Beta | 0.37 | ||||
| Market Capitalization | 713.81 B | ||||
| Total Asset | 64.01 B | ||||
| Retained Earnings | 10.31 B | ||||
| Working Capital | (1.57 B) | ||||
| Current Asset | 12.57 B | ||||
| Current Liabilities | 8.23 B | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 1.83 % | ||||
| Net Asset | 64.01 B | ||||
| Last Dividend Paid | 4.52 |
About Eli Lilly Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Eli Lilly Piotroski F Score and Eli Lilly Altman Z Score analysis. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.13 | Dividend Share 4.52 | Earnings Share 5.82 | Revenue Per Share 37.908 | Quarterly Revenue Growth 0.281 |
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.